Evidence map›Paper›PMID 39741266›Full record

ReviewBMC cancer2024

A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.

Tao Luan, Jianqing Hao, Yingying Gu, Ping He, Yijia Li, Liqiang Wang, Haiyi Deng, Wenhui Guan, Xinqing Lin, Xiaohong Xie and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. The Role of AI in Clinical Trial Design and Scientific Writing.Cardiovascular and interventional radiology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The role of HOXA1 in cancer and targeted therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  10. Review
  11. Article
  12. Non-small-cell lung cancer.Nature reviews. Disease primers · 2024
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tao LuanFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
Jianqing HaoFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
Yingying GuNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Ping HeNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Yijia LiNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Liqiang WangNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Haiyi DengNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Wenhui GuanNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Xinqing LinNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Xiaohong XieNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Yu DengNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Shuaiying WangAnesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Changchun WangAnesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Jingxu LiNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Ru LiNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Yang LuanFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
Gang YangFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
Yunhui ZhangFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China. Yunhuizhang3188@126.com.
Nanshan ZhongFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China. Nanshan@vip.163.com.
Chengzhi ZhouNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China. doctorzcz@163.com.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-HS202102-0118Guangzhou Science and Technology Major Clinical Projectc 2023C-DZ06National Key R&D Program of China （2021YFC2301101）Zhongnanshan Medical Foundation of Guangdong Province ZNSA-2020003
6 · The paper itself

Abstract

objectiveThe aim of this study is to explore the clinicopathological features, radiographic manifestations, treatment options, and prognosis of primary pulmonary angiosarcoma (PPAS).

methodWe summarized and analyzed the clinical data of 11 patients with primary pulmonary angiosarcoma treated at the First Affiliated Hospital of Guangzhou Medical University between January 2018 and January 2024. A retrospective analysis was conducted in conjunction with a review of the relevant literature.

resultsAmong the 11 cases, the primary symptoms were nonspecific respiratory issues, with chest pain, cough, and shortness of breath being the most common. Initial diagnosis was correct in only 2 cases, while the remaining 9 cases were misdiagnosed as other conditions, such as lung nodules, infections, or pulmonary embolism. All patients were ultimately diagnosed via pathology, with CD31 and CD34 showing a high positivity rate of 60%. Of the 11 patients, 9 have died, and 2 remain alive. The average survival period was 13.2 months.Based on the number of lesions, PPAS was categorized into three types: solitary, multiple, and invasive pulmonary artery. The average survival period for the solitary type (2 cases) was 15.5 months, for the multiple type (5 cases) was 6.6 months, and for the pulmonary artery type (4 cases) was 20.5 months. Among the 3 patients who underwent surgery, the median overall survival (OS) was 23.0 months, whereas for the 8 non-surgical patients, the median OS was 9.7 months.

conclusionPrimary pulmonary angiosarcoma is a rare, highly aggressive vascular malignancy characterized by nonspecific clinical symptoms and a tendency for metastasis and pulmonary artery embolism. Currently, no effective treatment exists, and the overall prognosis is poor.

Indexed as

HemangiosarcomaLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesImagingPulmonary vascular sarcomaRare tumorSurvival period

Identifiers

PMID39741266
PMCPMC11687076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.